Epitalon
Monograph · CTetrapeptide thought to upregulate telomerase. Long-term human evidence limited.
How it clearsHalf cleared in ~1h. Most (~96%) gone by ~5h.
Evidence is experimental. Most claims trace to limited human studies or animal models. Treat as a research direction, not a protocol.
Ala-Glu-Asp-Gly. Russian-developed. Animal and small Russian human studies report telomerase activation and pineal gland modulation. Western replication is sparse. Most longevity claims trace to a single research lineage.
Early-stage — most claims are extrapolated from animal or in-vitro studies with no human replication at scale. Longevity effects specifically resist short-term human measurement, which means both positive and negative signals are genuinely difficult to read.
Western clinical evidence is thin. Most peer-reviewed literature is from a small Russian research group (Khavinson). Source quality from grey-market vendors varies considerably.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyStack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Khavinson lab's core claim is that Epitalon (and the broader Khavinson-peptide family) extends lifespan in elderly populations via telomerase activation and pineal regulation. Decades of Russian-language publications. Western validation absent; replication attempts limited.
F-tier — "biohackers' wet dream... the human studies are extremely thin and inconsistent. It really hasn't been shown in any substantive way to do what it's supposed to do." Recommends GHK-Cu or growth hormone secretagogues instead for anti-aging.
No registered Phase 2/3 trials of Epitalon for any indication in Western databases. Mechanism claims (telomerase activation in vivo) are not supported by independent replication. The Khavinson-lineage publications stand outside the Western peer-review system.
Source →Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
FDA Cat. 2 removed Apr 2026 — PCAC review Jul 23-24, 2026
FDA's Pharmacy Compounding Advisory Committee scheduled to review the first cohort of peptides removed from Category 2 in April 2026. The 7 peptides on this docket are the highest-profile community names — BPC-157, TB-500, MOTS-c, Epitalon, DSIP, Semax, KPV.
FDA published a Federal Register notice on April 15 2026 removing 12 peptides from the Category 2 ('significant safety concerns') compounding list, paving the way for PCAC review for inclusion on the 503A bulks list. Peptides removed: BPC-157, TB-500, Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, MK-677, Melanotan II, KPV, Semax, LL-37.
FDA's Pharmacy Compounding Advisory Committee categorized a wide list of peptides as Category 2 ('significant safety concerns'), effectively banning their compounding at 503A and 503B pharmacies. Affected: BPC-157, TB-500, Epitalon, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, Selank, LL-37 and others.
Epitalon is on the PCAC docket for July 23–24, 2026. Notify me when the ruling drops.
No spam. Only alerts for this compound. Unsubscribe anytime.
Pre-filled with this compound's published dose range: 5-10 mg · daily for 10–20 days, cycled
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Russian-source predominantly. Bodybuilder-coach Eric Janicki rated F-tier April 2026 — thin human evidence. Price reflects supply, not validated efficacy.
As of 2026-04No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.